WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Abbott

AbbottAt Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

www.abbott.com

Abbott RSS Channel

Filters
List of articles in category Abbott
Title Published Date
Abbott Launches New Psoriasisanswers.com Web site 13 August 2010
Abbott Reports Strong Second Quarter Results 21 July 2010
Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix 17 June 2010
Americans Are Not Taking Action to Protect Themselves Against Muscle Loss 10 June 2010
Abbott to Become No. 1 Pharmaceutical Company in India 21 May 2010
RA.com Features Interactive Resource to Help People Living with Rheumatoid Arthritis 14 May 2010
Abbott licenses 24 Zydus pharmaceutical products for 15 high-growth emerging markets 12 May 2010
Despite Concern, Americans Aren't Protecting Themselves Against Diabetes 28 April 2010
Abbott Reports Strong First Quarter Results 21 April 2010
Abbott Completes Acquisition of STARLIMS Technologies 23 March 2010
Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology 15 March 2010
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 10 March 2010
Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals 03 March 2010
Abbott Completes Acquisition of Solvay Pharmaceuticals 16 February 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir® (ritonavir) Tablets 15 February 2010
Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter 28 January 2010
Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts 20 January 2010
Abbott to Provide $1 Million in Funding, Products to Help Address Health Needs in Haiti 14 January 2010
Abbott's XIENCE V(R) Approved in Japan - Second Largest Drug Eluting Stent Market Worldwide 11 January 2010
Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 15 December 2009
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • End
Tahmeena

Business & Industry

  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed
  • Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
  • NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs

Research & Development

  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic
  • Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations
  • Study identifies potential new approach for treating lupus

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Abbott
  4. Abbott announces CE Mark and first use of the world's first smartphone compatible insertable cardiac monitor

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.